Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis.

Kang EG, Narayana PK, Pouliquen IJ, Lopez MC, Ferreira-Cornwell MC, Getsy JA.

Allergy. 2019 Sep 13. doi: 10.1111/all.14050. [Epub ahead of print] No abstract available.

PMID:
31515809
2.

Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.

Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M.

JAMA Psychiatry. 2017 Sep 1;74(9):903-910. doi: 10.1001/jamapsychiatry.2017.1889.

3.

A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.

Gasior M, Hudson J, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL.

J Clin Psychopharmacol. 2017 Jun;37(3):315-322. doi: 10.1097/JCP.0000000000000702.

4.

Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.

McElroy SL, Mitchell JE, Wilfley D, Gasior M, Ferreira-Cornwell MC, McKay M, Wang J, Whitaker T, Hudson JI.

Eur Eat Disord Rev. 2016 May;24(3):223-31. doi: 10.1002/erv.2418. Epub 2015 Dec 1.

PMID:
26621156
5.

Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.

McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M.

Neuropsychopharmacology. 2016 Apr;41(5):1251-60. doi: 10.1038/npp.2015.275. Epub 2015 Sep 9.

6.

Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.

McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, Wang J, Whitaker T, Jonas J, Gasior M.

JAMA Psychiatry. 2015 Mar;72(3):235-46. doi: 10.1001/jamapsychiatry.2014.2162.

PMID:
25587645
7.

A generalized estimating equation approach to analysis of maintenance of wakefulness testing in a study of lisdexamfetamine dimesylate, armodafinil, and placebo in sleep-deprived adults.

Roth T, Freeman J, Zammit G, Donnelly P, Gao J, Ferreira-Cornwell MC, Gasior M.

J Clin Psychopharmacol. 2014 Oct;34(5):642-4. doi: 10.1097/JCP.0000000000000177.

PMID:
25180798
8.

Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep loss.

Gasior M, Freeman J, Zammit G, Donnelly P, Gao J, Ferreira-Cornwell MC, Roth T.

J Clin Psychopharmacol. 2014 Dec;34(6):690-6. doi: 10.1097/JCP.0000000000000202.

PMID:
25159886
9.

Participant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Childress AC, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, Findling RL.

J Child Adolesc Psychopharmacol. 2014 May;24(4):210-7. doi: 10.1089/cap.2013.0077. Epub 2014 May 9.

10.

A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, Childress AC.

J Child Adolesc Psychopharmacol. 2013 Feb;23(1):11-21. doi: 10.1089/cap.2011.0088.

PMID:
23410138
11.

Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.

Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.

J Clin Psychiatry. 2012 Jul;73(7):977-83. doi: 10.4088/JCP.11m07430. Epub 2012 Jun 12.

PMID:
22780921
12.

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.

J Am Acad Child Adolesc Psychiatry. 2011 Apr;50(4):395-405. doi: 10.1016/j.jaac.2011.01.007. Epub 2011 Mar 3.

PMID:
21421179
13.

Remodeling the intercalated disc leads to cardiomyopathy in mice misexpressing cadherins in the heart.

Ferreira-Cornwell MC, Luo Y, Narula N, Lenox JM, Lieberman M, Radice GL.

J Cell Sci. 2002 Apr 15;115(Pt 8):1623-34.

14.

Rescuing the N-cadherin knockout by cardiac-specific expression of N- or E-cadherin.

Luo Y, Ferreira-Cornwell M, Baldwin H, Kostetskii I, Lenox J, Lieberman M, Radice G.

Development. 2001 Feb;128(4):459-69.

15.

N-cadherin function is required for differentiation-dependent cytoskeletal reorganization in lens cells in vitro.

Ferreira-Cornwell MC, Veneziale RW, Grunwald GB, Menko AS.

Exp Cell Res. 2000 Apr 10;256(1):237-47.

PMID:
10739670
16.

Precocious mammary gland development in P-cadherin-deficient mice.

Radice GL, Ferreira-Cornwell MC, Robinson SD, Rayburn H, Chodosh LA, Takeichi M, Hynes RO.

J Cell Biol. 1997 Nov 17;139(4):1025-32.

Supplemental Content

Loading ...
Support Center